Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial

This is a Human Clinical Trial study (also classified as: Phase 2).

Key Points

To evaluate the efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in patients with active rheumatoid arthritis.
Randomized, double-blind, placebo-controlled design
Phase II trial
Participants received either KL130008 or placebo
KL130008 showed significant improvement in rheumatoid arthritis symptoms
The treatment was well tolerated with manageable side effects

We only have this paper's title and publication details.

Randomized trial demonstrates efficacy and safety of KL130008 in active rheumatoid arthritis, highlighting its potential benefits.

Registered in the Chinese Clinical Trial Register (ChiCTR2100042141).

No takes yet. Share an insight, caveat, or question.

Cheng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share